Vermillion, Inc.

AUSTIN, Texas, June 11, 2013 /PRNewswire/ -- Vermillion, Inc.'s (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, OVA1® has received a new statement on clinical validation and medical use issued by the Society of Gynecologic Oncology (SGO). Citing peer-reviewed publications from two pivotal clinical studies of ... read more

AUSTIN, Texas, May 15, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and women's health, reported on its financial results for the first quarter ended March 31, 2013. Q1 2013 Financial Results Total revenue in the first quarter of 2013 was $328,000, compared to $312,000 ... read more

AUSTIN, Texas, May 9, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and women's health, announced that Oracle Investment Management, Jack W. Schuler, Matthew W. Strobeck and other investors, have agreed, subject to closing conditions, to make an initial investment ... read more

AUSTIN, Texas, May 8, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and women's health, joins ovarian cancer organizations around the world in recognizing May 8 as World Ovarian Cancer Day. On this day, ovarian cancer organizations are ... read more

AUSTIN, Texas, May 1, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and women's health, will hold a conference call on Wednesday, May 15, 2013, at 4:30 p.m. Eastern time to discuss results for the first quarter ended March 31, ... read more

AUSTIN, Texas, April 17, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and women's health, announced the signing of a cooperative research and development agreement (CRADA) with the U.S. Army Medical Research and Materiel Command (USAMRMC). The agreement kicks off a ... read more

AUSTIN, Texas, March 19, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and women's health, has appointed Bruce A. Huebner as chairman effective March 18, 2013. He succeeds James S. Burns, who will continue to serve on the board ... read more

AUSTIN, Texas, March 13, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and women's health, has appointed Thomas McLain as president and chief executive officer effective March 18, 2013. He succeeds Bruce Huebner, the company's interim chief executive officer, who ... read more

AUSTIN, Texas, Feb. 19, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and vascular medicine, will hold a conference call on Wednesday, February 20, 2013, at 4:30 p.m. ET to discuss full results for its fourth quarter and year ended ... read more

AUSTIN, Texas, Feb. 19, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and vascular medicine, has been invited to participate in Lazard Capital Market's 5th Annual Medical Technology Snowbird Conference. The conference is being held at the Cliff Lodge Snowbird ... read more

AUSTIN, Texas, Feb. 8, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and vascular medicine, will hold a conference call on Wednesday, February 20, 2013, at 4:30 p.m. ET to discuss preliminary results for its fourth quarter and full year ... read more